Main contents starts here
Overview
Takeda has created numerous pharmaceutical products, including the four international strategic products (Leuprorelin Acetate, Lansoprazole, Candesartan Cilexetil, Pioglitazone Hydrochloride), which are distributed in many countries around the world. In the hopes of continuously developing superior pharmaceutical products to follow these and delivering at the earliest possible date the new drugs that are eagerly awaited by patients, we are, being guided by the MPDRAP (Marketing, Production, Development, Research, Alliance, Patent) strategy, committed to the development of new drugs by focusing our management resources on the four core therapeutic areas of: life-style related diseases; oncology and urological diseases; central nervous system diseases, and gastroenterological diseases.
R&D News
- August 29, 2008
Takeda and Affymax Provide Clinical Development Update for Hematide™ in Chemotherapy-induced Anemia - July 16, 2008
Antiosteoporotic drugs “Actonel® 17.5 mg tablets” and “Benet® 17.5 mg tablets” received approval for additional indication in patients with Paget’s disease of bone: Both come in new packages. - June 30, 2008
Takeda Submitted a New Drug Application for Anti-Cancer Agent, panitumumab (recombinant) - June 23, 2008
FDA Approves VELCADE® (BORTEZOMIB) for Injection for Patients with Previously Untreated Multiple Myeloma - June 17, 2008
Takeda to Appeal EMEA Negative Opinion on ramelteon for the Treatment of Primary Insomnia
Latest Publications of Takeda Research Laboratories
 |
R&D At a Glance
| Main R&D Facilities | The Tsukuba Research Center (Tsukuba, Japan) |
| The Osaka Research Center (Osaka, Japan) | |
| Takeda Research Investment, Inc. (New York, NY, U.S.) | |
| Takeda San Diego, Inc. (San Diego, CA, U.S.) | |
| Takeda San Francisco, Inc. (San Francisco, CA, U.S.) | |
| Takeda Cambridge Limited (Cambridge, U.K.) | |
| Takeda Singapore Pte Limited (Singapore) | |
| Japan Deveropment Center | |
| Takeda Global Research & Development Center, Inc. (Deerfield, IL. U.S.) | |
| Takeda Global Research & Development Centre(Europe), Ltd. (London, U.K.) | |
| Millennium Pharmaceuticals, Inc. (Cambridge, MA, U.S.) | |
| R&D Investment | ¥275.8billion ($2,758million) (FY2007) |
| Royalty Income | ¥50.7billion ($507million) (FY2007) |
| Core Therapeutic Areas |
Life style-related diseases, Oncology & Urological diseases, Central nervous system diseases, Gastroenterological diseases |
| Product Pipeline |
Takeda discloses ethical drugs under development that have reached phase I or higher status in at least one country among Japan, the U.S. and EU |
Note: The US dollar amounts represent translations of Japanese yen, for conbeniense only, at the rate of ¥100=US$1 approximate exchange rate at March 31, 2008.